Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market - Aarkstore Enterprise Market Research Rep
|
|
Drugs with new mechanisms, in particular Pfizer’s oral JAK inhibitor CP-690,550 and Chugai/Roche’s Actemra (tocilizumab), will launch for rheumatoid arthritis and should offer advantages over current therapies, but do not come without some safety signals. Late-stage pipeline launches will be a major contributor to market growth from $7.4 billion in 2008 to $11.5 billion in 2018. Scope *In-depth analysis of Phase II and III disease modifying drug candidates in the rheumatoid arthritis pipeline *Segmentation and analysis of the current rheumatoid arthritis pipeline by developmental phase, drug class and company *Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs *Focus on innovative early-stage drug development with assessment of future treatment of rheumatoid arthritis Highlights The shift from Western regions to countries in Eastern Europe and South America is now a prominent feature of modern rheumatoid arthritis clinical trials. This has led to variability in placebo and drug responses resulting in higher failure rates. This will continue to be a difficult hurdle for drug development in rheumatoid arthritis. Pfizer’s JAK inhibitor CP-690,550 blazes the trail for small molecule kinase inhibitors in rheumatoid arthritis. Despite efficacy being in line with biologics, product positioning, safety and cost are key debatable issues for uptake of this new drug upon launch in 2012. Forecasts sales in the seven major markets of $0.9 billion in 2018. Pre-launch awareness, robust clinical data and marketing capability leads to believe Actemra (tocilizumab; Roche/Chugai) will have a significant impact on the market. Safety remains a question, but physicians are willing to deal with issues highlighted in clinical trials. It expects Actemra to achieve blockbuster sales by 2015. Reasons to Purchase *Understand the major recent advances in the dynamic and constantly evolving rheumatoid arthritis pipeline *Evaluate the sales forecasts of key late-stage pipeline products to 2018 and understand new product positioning in this competitive market *Assess key opinion leaders’ views on the most advanced pipeline products including Pfizer’s JAK inhibitor CP-690,550 For more information, Please visit : http://www.aarkstore.com/ reports/ Pipeline-Insight-Disease-Modification-in-Rheumatoid-Arthritis-New-drug-targets-compete-in-crowded-market-33148.html User comments, Ratings and Reviews
Share this article:
You can Digg this article:
Contact Author: Click here to eMail
Akshay from 59.184.187.xxx
Article Taged as : pipeline, insight:, disease, modification, rheumatoid, arthritis, drug, targets, compete, crowded, market, aarkstore, enterprise, market, research, www.aarkstore.com, pipeline, insight:, disease, modification, rheumatoid, arthritis, drug, targets, compete, crowded, market, aarkstore, enterprise, market, research,
|
|
Article Statistics
Article Viewed 3092 times. News Article Source & Groups
You can find this article under group.
And brought to you by Channel ,
: : Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market - Aarkstore Enterprise Market Research Rep |
Related Stories
|
Today's Cartoon
Today's Cartoons provided by andertoons.com
Pipeline Insight: Disease Modification In Rheumatoid Arthritis - New Drug Targets Compete In Crowded Market - Aarkstore Enterprise Market Research Rep
All rights reserved. Copyright (R) 2006-2013 to News Album. All rights reserved.
Archived News Articles so far and still counting!
98506656 Visitors Yahoo we are happy for your presence.
Friday, May 24, 2013 4:07:06 PM